ReviewNanomaterials (Basel, Switzerland)2023
Application of Nanoparticles in Cancer Treatment: A Concise Review.
Review in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Multiscale investigation of radiation-induced structural evolution and stability of GdRSC advances · 2026Article
- Polymer Nanoparticles in Medical Applications-Future Directions.Nanomaterials (Basel, Switzerland) · 2026Review
- Chemotherapeutic efficacy of nano formulation capecitabine@SNPs and gamma radiation: a novel metronomic approach for breast cancer treatment.Drug delivery and translational research · 2026Article
- Targeting FN1 to overcome gemcitabine resistance in gallbladder cancer: Mechanistic insights and an iRGD-modified PEG-PLGA nanoparticle delivery strategy.Materials today. Bio · 2026Article
- The influence of multi-solvent systems on the electrospinning process.Scientific reports · 2026Article
- Smart integrated biomaterial systems for precision and optimized delivery of MSCs and their exosomes: Transforming wound healing and organ regeneration.Regenerative therapy · 2026Review
- From nanoscale to clinic: The growing impact of nanotechnology in translational drug delivery.ADMET & DMPK · 2026Review
- Targeted nano-drug delivery systems for tumor immunotherapy.Journal of pharmaceutical analysis · 2026Review
- Bridging bioactive metabolites ofFrontiers in pharmacology · 2026Review
- Preclinical Investigation of PLGA Nanocapsules and Nanostructured Lipid Carriers for Organoselenium Delivery: Comparative In Vitro Toxicological Profile and Anticancer Insights.Pharmaceutics · 2025Article
- Novel Adamantane-Sclareol Hybrids Exploit ROS Vulnerability to Overcome Multidrug-Resistance in Glioblastoma Cells.Molecules (Basel, Switzerland) · 2025Article
- Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications.Pharmaceutics · 2025Review
- The Nanocarrier Landscape─Evaluating Key Drug Delivery Vehicles and Their Capabilities: A Translational Perspective.ACS applied materials & interfaces · 2025Review
- Peptide-Based Nanoparticle for Tumor Therapy.Biomedicines · 2025Review
- Targeted delivery of chrysin and 5-fluorouracil on MDA-MB-231 cancer cells by a peptide-functionalized L-DOPA-imprinted polymer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Golden insights for exploring cancer: delivery, from genes to the human body using bimetallic Au/Ag nanostructures.Discover oncology · 2025Review
- Nanoparticles and Nanomaterials: A Review from the Standpoint of Pharmacy and Medicine.Pharmaceutics · 2025Review
- Green Myco-Synthesis of Zinc Oxide Nanoparticles UsingMicroorganisms · 2025Article
- Anticancer Nanoparticle Carriers of the Proapoptotic Protein CytochromePharmaceutics · 2025Review
- Circular RNAs in cancer.MedComm · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Timely diagnosis and appropriate antitumoral treatments remain of utmost importance, since cancer remains a leading cause of death worldwide. Within this context, nanotechnology offers specific benefits in terms of cancer therapy by reducing its adverse effects and guiding drugs to selectively target cancer cells. In this comprehensive review, we have summarized the most relevant novel outcomes in the range of 2010-2023, covering the design and application of nanosystems for cancer therapy. We have established the general requirements for nanoparticles to be used in drug delivery and strategies for their uptake in tumor microenvironment and vasculature, including the reticuloendothelial system uptake and surface functionalization with protein corona. After a brief review of the classes of nanovectors, we have covered different classes of nanoparticles used in cancer therapies. First, the advances in the encapsulation of drugs (such as paclitaxel and fisetin) into nanoliposomes and nanoemulsions are described, as well as their relevance in current clinical trials. Then, polymeric nanoparticles are presented, namely the ones comprising poly lactic-co-glycolic acid, polyethylene glycol (and PEG dilemma) and dendrimers. The relevance of quantum dots in bioimaging is also covered, namely the systems with zinc sulfide and indium phosphide. Afterwards, we have reviewed gold nanoparticles (spheres and anisotropic) and their application in plasmon-induced photothermal therapy. The clinical relevance of iron oxide nanoparticles, such as magnetite and maghemite, has been analyzed in different fields, namely for magnetic resonance imaging, immunotherapy, hyperthermia, and drug delivery. Lastly, we have covered the recent advances in the systems using carbon nanomaterials, namely graphene oxide, carbon nanotubes, fullerenes, and carbon dots. Finally, we have compared the strategies of passive and active targeting of nanoparticles and their relevance in cancer theranostics. This review aims to be a (nano)mark on the ongoing journey towards realizing the remarkable potential of different nanoparticles in the realm of cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.